Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q1 2025 Earnings Presentation
15 slides from Apellis Pharmaceuticals's earnings presentation, May 7, 2025
Slide 1: First Quarter 2025 Financial Results Conference Call
First Quarter 2025 Financial Results Conference Call May 7, 2025
Slide 2: Forward-looking statements
Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act o
Slide 3: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer T I M O T H Y S U L L I VA N Chief Financial Officer D AV I D A C H E S O N Executive Vice President of Commercial CAROLINE BAUMAL, M.D. Chief Medical Officer 3
Slide 4: SYFOVRE is the market leader in GA
SYFOVRE is the market leader in GA ~$130M in 1Q 2025 U.S. net product revenue, impacted by inventory dynamics and funding shortage at co-pay assistance programs 4% QoQ injection growth1 More than 60% of the overall market; share of new patient starts continued to grow, already reaching 55% by late A
Slide 5: EMPAVELI US launch in C3G and IC-MPGN in 3Q 2025
EMPAVELI US launch in C3G and IC-MPGN in 3Q 2025 July 28, 2025 PDUFA VALIANT 52-week results to be presented at ERA 2025 Congress Initiation of pivotal studies in DGF and FSGS expected in 2H 2025 Receive tiered, double-digit royalties (high teens to high twenties) on ex-US sales 5
Slide 6: Physician-driven 4Q 2024 inventory build followed by drawdown in 1Q 2025
Physician-driven 4Q 2024 inventory build followed by drawdown in 1Q 2025 Estimated Channel Inventory1 (ECP and Distributor) Physician-driven Channel • Physician orders sharply increased in buy-in drawdown December • Total channel inventory in 4Q 2024 increased at both physician offices and distribut
Slide 7: Total injections continue to increase QoQ
Total injections continue to increase QoQ SYFOVRE Total Injection Volume 1,2 1Q 2024 2Q 2024 3Q 2024 4Q 2024 1Q 2025 Trade Sample 1. Apellis data on file, excludes clinical trial injections. 2. This is an estimate derived and extrapolated from available ECP injection demand data estimated to be repr
Slide 8: Consolidated 1Q 2025 financial results
Consolidated 1Q 2025 financial results (In USD Millions) Three Months Ended March 31, 2025 2024 EMPAVELI U.S. Net Product Sales $19.7 $25.6 SYFOVRE U.S. Net Product Sales $130.2 $137.5 Licensing and Other Revenue $16.9 $9.3 Total Revenue $166.8 $172.3 Cost of Sales $34.4 $20.2 Expenses R&D Expenses
Slide 9: SYFOVRE leads in overall injection and new patient share
SYFOVRE leads in overall injection and new patient share Estimated Overall Total Injection Share (TRx) 1,2 Estimated Share of New to Brand (NBRx) 1,2 100% 100% 80% 80% 60% 61% 60% 55% 40% 39% 40% 45% 20% 20% 0% 0% 5/3 8/9 9/6 2/7 3/7 4/4 10/18 11/15 11/29 12/13 12/27 4/19 5/17 5/31 6/14 6/28 7/12 7/
Slide 10: Initiatives to drive SYFOVRE demand and new patient starts
Initiatives to drive SYFOVRE demand and new patient starts Connect with Highlight patients Importance through DTC of early intervention and campaign keeping patients on treatment Broaden Educate ECPs reach On best practices for to eyecare managing community reimbursement 10
Slide 11: SYFOVRE's differentiated profile
SYFOVRE’s differentiated profile Consistently demonstrated robust and increasing effects over time Approved for as few as 6 doses per year In a preferred position with many payers 11
Slide 12: Maximizing the potential for EMPAVELI in C3G and IC-MPGN
Maximizing the potential for EMPAVELI in C3G and IC-MPGN sNDA accepted and granted Priority Review • July 28th PDUFA • U.S. launch expected in 2H 2025, if approved Pre-launch activities underway • Highlight the urgency for treatments that address underlying disease pathology • Ensure rapid and seaml
Slide 13: We expect use of EMPAVELI across all disease severities
We expect use of EMPAVELI across all disease severities Post transplant ~5K C3G / IC-MPGN Severe patients estimated in U.S. 1 Moderate Mild 1. 2024 claims data analysis (patients with confirmed diagnosis). Servais et al. Kidney Int. 2012; 82(4): 454. Iatropoulos et al, Mol Immunol. 2016; 71: 131 13
Slide 14: EMPAVELI continues to elevate the standard of care in PNH
EMPAVELI continues to elevate the standard of care in PNH As of March 31, 2025: • ~$20 million in 1Q 2025 U.S. net product revenue • ~97% patient compliance rate • Continued strong safety profile with zero meningococcal infections due to encapsulated bacteria 14
Slide 15: First Quarter 2025 Financial Results Conference Call
First Quarter 2025 Financial Results Conference Call May 7, 2025
Apellis Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix